Contraindicated (1)bortezomib will raise the amount or outcome of mavacamten by influencing hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may possibly maximize mavacamten systemic exposure, leading to coronary heart failure on account of systolic dysfunction. levoketoconazole will improve the amount or impact of bortezomib by impacting hepat... https://gsk12676442.madmouseblog.com/7220576/the-5-second-trick-for-dup-747